Combination of Epirubicin and Lonidamine for Treatment of Advanced Breast Cancer

Moraglio, L.; Brema, Fulvio; Pastorino, G; Martini, Maria Cristina; Vallauri, M.

doi:10.1177/030089169508100207

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Combination of Epirubicin and Lonidamine for Treatment of Advanced Breast Cancer

Abstract: Although some patients seem to have benefited from the combination at the dose levels of the drug used in the study, the therapeutic advantages of addition of lonidamine remain unclear.

Cited by 8 publications

References 10 publications

Enhancement of colorectal tumor targeting using a novel biparatopic monoclonal antibody against carcinoembryonic antigen in experimental radioimmunoguided surgery

Enhancement of colorectal tumor targeting using a novel biparatopic monoclonal antibody against carcinoembryonic antigen in experimental radioimmunoguided surgery

Radioimmunoscintigraphy

Tumour Targeting Using Peptides, Monoclonal Antibodies and Fragments

Contact Info

Product

Resources

About